Overview of current treatment of neuroblastoma.
Neuroblastoma is the second most common solid tumor in infants and children. Improvement of therapy for stage IV patients remains the major goal of research in treatment of neuroblastoma. New approaches under study are focused in four main areas: (a) phase II studies; (b) mega-therapy procedures; (c) targeted therapy; and (d) immunotherapy. Future approaches will be closely linked to progress in laboratory investigation and more efficient use of currently available drugs. Of all the childhood malignancies, this is the one tumor where such an approach is most likely to be effective.
Philip
T
T
Centre Léon Berard, Lyon, France.
D000367:Age Factors; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D016026:Bone Marrow Transplantation; D002675:Child, Preschool; D003131:Combined Modality Therapy; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use; D016219:Immunotherapy, Adoptive; D015994:Incidence; D007223:Infant; D007231:Infant, Newborn; D007376:Interleukin-2 / Q000627:therapeutic use; D009367:Neoplasm Staging; D009447:Neuroblastoma / Q000453:epidemiology / Q000473:pathology / Q000628:therapy*; D010166:Palliative Care; D011379:Prognosis; D012074:Remission Induction; D015996:Survival Rate; D016896:Treatment Outcome
D007155:Immunologic Factors; D007376:Interleukin-2